Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 8 of 8 results for tenofovir disoproxil

  1. Tenofovir disoproxil for the treatment of chronic hepatitis B (TA173)

    Evidence-based recommendations on tenofovir disoproxil for treating chronic hepatitis B.

    Technology appraisal guidance
    Published
    22 July 2009
    View recommendations

    Sections for TA173

  2. Hepatitis B (chronic): diagnosis and management (CG165)

    This guideline covers assessing and managing chronic hepatitis B in children, young people and adults. It aims to improve care for people with hepatitis B by specifying which tests and treatments to use for people of different ages and with different disease severities.

    Clinical guideline
    Last updated
    20 October 2017
    View recommendations

    Sections for CG165

  3. Cabotegravir for preventing HIV-1 in adults and young people [ID6255]

    In development [GID-TA11304] Expected publication date: 29 January 2025

    Technology appraisal guidance
    In development

  4. Long-term safety of tenofovir disoproxil in chronic hepatitis B:- Further research should be undertaken to determine the long-term safety of tenofovir disoproxil, including the risk of clinically significant hypophosphataemia and related bone toxicity, in people with chronic hepatitis B. The cost effectiveness of routine monitoring for phosphate loss and bone disease in people with chronic hepatitis B who are receiving tenofovir disoproxil treatment needs further evaluation.

    safety of tenofovir disoproxil in chronic hepatitis B:- Further research should be undertaken to determine the long-term safety of...

    Research recommendation
    Published
    9 June 2015

  5. Hepatitis B (adults) - entecavir and tenofovir disoproxil fumarate [ID111]

    Discontinued [GID-TAG414]

    Technology appraisal guidance
    Discontinued

  6. Cabotegravir with rilpivirine for treating HIV-1 (TA757)

    Evidence-based recommendations on cabotegravir (Vocabria) with rilpivirine (Rekambys) for treating HIV-1 in adults. This includes adults with virological suppression (HIV-1 RNA fewer than 50 copies/ml) on a stable antiretroviral regimen, and without any evidence of viral resistance to, and no previous virological failure with, any non-nucleoside reverse transcriptase inhibitors or integrase inhibitors.

    Technology appraisal guidance
    Published
    5 January 2022
    View recommendations

    Sections for TA757

  7. Pre-exposure prophylaxis of HIV in adults at high risk: Truvada (emtricitabine/tenofovir disoproxil) (ESNM78)

    This advice has been updated and replaced by NICE guideline NG221.

    Evidence summary
    Published
    5 October 2016

  8. Research recommendations

    safety of tenofovir disoproxil in chronic hepatitis B:- Further research should be undertaken to determine the long-term safety of...